Glass Wealth Management Co LLC Buys 613 Shares of Merck & Co., Inc. (NYSE:MRK)

Glass Wealth Management Co LLC increased its position in Merck & Co., Inc. (NYSE:MRK) by 1.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 33,269 shares of the company’s stock after acquiring an additional 613 shares during the quarter. Merck & Co., Inc. comprises about 2.1% of Glass Wealth Management Co LLC’s investment portfolio, making the stock its 16th biggest position. Glass Wealth Management Co LLC’s holdings in Merck & Co., Inc. were worth $3,778,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. AM Squared Ltd acquired a new stake in shares of Merck & Co., Inc. during the third quarter worth approximately $34,000. Peterson Financial Group Inc. bought a new position in shares of Merck & Co., Inc. in the 3rd quarter worth $36,000. Itau Unibanco Holding S.A. bought a new stake in shares of Merck & Co., Inc. in the 2nd quarter valued at about $39,000. Abich Financial Wealth Management LLC increased its stake in Merck & Co., Inc. by 121.8% in the second quarter. Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock valued at $40,000 after purchasing an additional 179 shares in the last quarter. Finally, Quarry LP acquired a new stake in Merck & Co., Inc. during the 2nd quarter worth $42,000. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Price Performance

MRK opened at $96.31 on Monday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.15 and a current ratio of 1.36. The company’s 50-day simple moving average is $108.84 and its two-hundred day simple moving average is $118.83. Merck & Co., Inc. has a 52-week low of $94.48 and a 52-week high of $134.63. The stock has a market capitalization of $243.63 billion, a P/E ratio of 20.19, a P/E/G ratio of 1.38 and a beta of 0.40.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, October 31st. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $1.50 by $0.07. The firm had revenue of $16.66 billion during the quarter, compared to analyst estimates of $16.47 billion. Merck & Co., Inc. had a return on equity of 36.42% and a net margin of 19.23%. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.13 earnings per share. As a group, analysts predict that Merck & Co., Inc. will post 7.75 EPS for the current year.

Wall Street Analysts Forecast Growth

MRK has been the subject of a number of research reports. Barclays lowered their target price on Merck & Co., Inc. from $142.00 to $140.00 and set an “overweight” rating for the company in a report on Monday, October 7th. Morgan Stanley dropped their price target on Merck & Co., Inc. from $130.00 to $123.00 and set an “equal weight” rating on the stock in a research note on Friday, November 1st. Citigroup decreased their target price on shares of Merck & Co., Inc. from $140.00 to $130.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. BMO Capital Markets cut their price target on shares of Merck & Co., Inc. from $150.00 to $136.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Finally, Truist Financial cut their target price on Merck & Co., Inc. from $132.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, ten have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and an average price target of $130.86.

About Merck & Co., Inc.

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.